(资料图)
证券时报e公司讯，翰宇药业(300199)在互动平台表示，公司HY3000鼻喷雾剂于2023年1月27日晚收到了美国食品药品监督管理局（FDA）的《新药临床试验申请（IND）受理通知书》，同时公司也将根据市场动态适时调整注册申报策略。
(资料图)
证券时报e公司讯，翰宇药业(300199)在互动平台表示，公司HY3000鼻喷雾剂于2023年1月27日晚收到了美国食品药品监督管理局（FDA）的《新药临床试验申请（IND）受理通知书》，同时公司也将根据市场动态适时调整注册申报策略。
2023-01-28
2023-01-28
2023-01-28
2023-01-27
2023-01-27
2023-01-27
2023-01-26
2023-01-26
2023-01-26
2023-01-25
2023-01-25
2023-01-25
2023-01-24
2023-01-24
2023-01-24
2023-01-24
2023-01-23
2023-01-23
2023-01-23
2023-01-22
2023-01-22
2023-01-22
2023-01-21
2023-01-21
2023-01-21
2023-01-20
2023-01-20
2023-01-20
2023-01-20
2023-01-20
2023-01-19
2023-01-19
2023-01-19
2023-01-19
2023-01-19
2023-01-18
2023-01-18
2023-01-18
2023-01-18
2023-01-18
2023-01-17
2023-01-17
2023-01-17
2023-01-17
2023-01-17
2023-01-16
2023-01-16
2023-01-16
2023-01-16
2023-01-15
2023-01-15
2023-01-14
2023-01-14
2023-01-13
2023-01-13
2023-01-13
2023-01-13
2023-01-12
2023-01-12
2023-01-12
2023-01-12
2023-01-12
2023-01-12
2023-01-11
2023-01-11
2023-01-11
2023-01-11
2023-01-11
2023-01-10
2023-01-10
2023-01-10
2023-01-10
2023-01-10
2023-01-10
2023-01-10
2023-01-10
2023-01-09
2023-01-09
2023-01-09
2023-01-09
2023-01-09
2023-01-09
2023-01-07
2023-01-06
2023-01-06
2023-01-06
2023-01-06
2023-01-06
2023-01-05
2023-01-05
2023-01-05
2023-01-04
2023-01-04
2023-01-04
2023-01-04
2023-01-04
2023-01-03
2023-01-03
2023-01-03
2023-01-03